SCHEMBL183208

SCHEMBL183208

COc1ccc(-c2ccc3ncnc(-c4ccc(C(=O)O)cc4)c3c2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 7/20 0.58
PIK3CA P42336 7/20 0.58
PIK3CB P42338 7/20 0.58
PIK3CG P48736 7/20 0.58
KCNH2 Q12809 1/20 0.58
MTOR P42345 1/20 0.57
BRAF P15056 4/20 0.54
RAF1 P04049 3/20 0.54
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA7 P43166 1/20 0.49
TPMT P51580 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
PDE4A P27815 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182495 0.90 PIK3CA (0.58) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL183018 0.89 PIK3CD (0.57) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL183174 0.89 PIK3CA (0.57) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182885 0.87 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182844 0.87 CLK4 (0.59) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182889 0.87 PIK3CD (0.67) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182536 0.87 PIK3CA (0.60) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182932 0.87 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182560 0.87 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2
SCHEMBL182794 0.86 PIK3CD (0.70) PIK3CDPIK3CAPIK3CBPIK3CGKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US disclosed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA PIK3CD 6/4885PIK3CA 3/4885PIK3CB 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.